Semaglutide use was associated with lower psychiatric hospitalization and bipolar-relapse hospitalization risks among Swedish adults with bipolar disorder receiving antidiabetic medication, although the observational findings did not establish a therapeutic effect.

The FDA granted Breakthrough Therapy designation to DT120, an oral lysergide formulation under investigation for major depressive disorder, based on phase 3 findings suggesting rapid and sustained antidepressant effects, though the treatment remains investigational and unapproved.

Baseline activity in the left dorsolateral prefrontal cortex and right precuneus during working memory and emotion-regulation tasks was associated with depression severity one year later in young adults at elevated risk for affective disorders, but not with future mania symptoms.

A comprehensive prescribing guide argues that orally administered racemic ketamine may offer a low-cost, accessible option for severe, suicidal, or treatment-resistant depression, while emphasizing structured protocols, monitoring, informed consent, and careful patient selection.

Prior ayahuasca experience was associated with lower self-reported depression, stress, and alcohol use among Brazilian ceremony participants, while also correlating with stronger spiritual wellbeing and metaphysical beliefs in an observational study that did not establish causality.

Among nearly 1 million UK adults, preference for very hot beverages and consumption of at least six hot drinks daily were associated with higher esophageal squamous cell carcinoma risk, but not materially with adenocarcinoma.